Are you over 18 and want to see adult content?
More Annotations
![A complete backup of easyurdutyping.com](https://www.archivebay.com/archive/53814c10-65c5-45fa-8dbc-16a5e73ecc07.png)
A complete backup of easyurdutyping.com
Are you over 18 and want to see adult content?
![A complete backup of cinemadelwest.com.br](https://www.archivebay.com/archive/553cdc70-c082-49fa-b782-5febde09b30e.png)
A complete backup of cinemadelwest.com.br
Are you over 18 and want to see adult content?
![A complete backup of sonaleninde.tumblr.com](https://www.archivebay.com/archive/81900cc0-97d1-4156-98a7-ad9d68940d9c.png)
A complete backup of sonaleninde.tumblr.com
Are you over 18 and want to see adult content?
![A complete backup of sportslogohistory.com](https://www.archivebay.com/archive/e6b4ec48-efe0-48b3-8a34-c389005f4f14.png)
A complete backup of sportslogohistory.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of guiadonomadedigital.com](https://www.archivebay.com/archive/82ff9aea-de89-4e7c-93c6-31b6e8a34246.png)
A complete backup of guiadonomadedigital.com
Are you over 18 and want to see adult content?
![A complete backup of giveasyoulive.com](https://www.archivebay.com/archive/54d75c5f-fdf3-4b27-b1c0-8634d08872d3.png)
A complete backup of giveasyoulive.com
Are you over 18 and want to see adult content?
![A complete backup of championfreight.co.nz](https://www.archivebay.com/archive/70e024bc-0628-4b8a-89fb-bf878184612d.png)
A complete backup of championfreight.co.nz
Are you over 18 and want to see adult content?
![A complete backup of freewalldownload.com](https://www.archivebay.com/archive/25c178de-cd21-43bc-90ba-2ff12fbc8fc3.png)
A complete backup of freewalldownload.com
Are you over 18 and want to see adult content?
![A complete backup of trucosdefamilia.com](https://www.archivebay.com/archive/e7a7606c-808d-4041-8080-dd86620478f7.png)
A complete backup of trucosdefamilia.com
Are you over 18 and want to see adult content?
![A complete backup of orchidsandpeonies.com](https://www.archivebay.com/archive/a6379728-1e82-4ca2-8da0-201adb5913c9.png)
A complete backup of orchidsandpeonies.com
Are you over 18 and want to see adult content?
![A complete backup of thejazzcafelondon.com](https://www.archivebay.com/archive/6c70ac38-40a9-4281-9986-9a31fddc3678.png)
A complete backup of thejazzcafelondon.com
Are you over 18 and want to see adult content?
Text
late-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
ARGUS SAFETY
Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY
Argus Val - speargv2. 02-JUN-2021 00:19:15. Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. -Argus Safety Japan.
SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
ARGUS SAFETY
Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY
Argus Val - speargv2. 02-JUN-2021 00:19:15. Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. -Argus Safety Japan.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Development Pipeline. An investigational long-acting granulocyte colony-stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia. The Biologics License Application (BLA) was filed in December, 2019, with a PDUFA date of October 24, 2020. On October 26, 2020, the company announced that the FDA informedthe company that
SPECTRUM PHARMACEUTICALS, INC. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has a late-stage pipeline that hasthe
SPECTRUM PHARMACEUTICALS, INC. Spectrum has a broad and diversified portfolio of proprietary drugs in various stages of development with a focus on oncology. This includes promising late-stage as well as early-stage drug candidates with unique formulations and mechanisms of action. These potential products address the needs of seriously ill patients, such as new treatmentINVESTOR RELATIONS
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncology and Hematology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
SPECTRUM PHARMACEUTICALS, INC. At Spectrum, we are committed to a corporate culture of compliance and integrity. Our Compliance and Ethics Program is a set of internal controls and standards that promote adherence to pharmaceutical industry statutes, regulations, and requirements of the federal health care programs with respect to the development, manufacturing, marketing and selling of products. SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGE Global Corporate Office Spectrum Pharmaceuticals. 11500 S. Eastern Avenue #240 Henderson, NV 89052 Phone: (702) 835-6300 Fax: (702)260-7405
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
ARGUS SAFETY
Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY
Argus Val - speargv2. 02-JUN-2021 00:19:15. Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. -Argus Safety Japan.
SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
ARGUS SAFETY
Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY
Argus Val - speargv2. 02-JUN-2021 00:19:15. Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. -Argus Safety Japan.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Development Pipeline. An investigational long-acting granulocyte colony-stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia. The Biologics License Application (BLA) was filed in December, 2019, with a PDUFA date of October 24, 2020. On October 26, 2020, the company announced that the FDA informedthe company that
SPECTRUM PHARMACEUTICALS, INC. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has a late-stage pipeline that hasthe
INVESTOR RELATIONS
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncology and Hematology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, SPECTRUM PHARMACEUTICALS, INC. At Spectrum, we are committed to a corporate culture of compliance and integrity. Our Compliance and Ethics Program is a set of internal controls and standards that promote adherence to pharmaceutical industry statutes, regulations, and requirements of the federal health care programs with respect to the development, manufacturing, marketing and selling of products. SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGE Global Corporate Office Spectrum Pharmaceuticals. 11500 S. Eastern Avenue #240 Henderson, NV 89052 Phone: (702) 835-6300 Fax: (702)260-7405
SPECTRUM PHARMACEUTICALS, INC. Phase 2 trials; Ozarelix has the potential to be an important addition in treating hormone-dependent prostate cancer patients due to its ability to induce prolonged testosterone suppression without inducing an initial testosterone surge and associated risk of clinical flare and cancer progression observed in currently marketed LHRH agonists, as shown in healthy volunteers in early trials. SPECTRUM PHARMACEUTICALS, INC. Spectrum’s Medical Affairs department is the company’s primary customer-facing scientific exchange organization. The department includes functions dedicated to supporting the non-promotional scientific information needs of the healthcare community. These functions include Medical Information, Medical Communications, FieldMedical Affairs
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
ARGUS SAFETY
Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY
Argus Val - speargv2. 02-JUN-2021 00:19:15. Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. -Argus Safety Japan.
SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
ARGUS SAFETY
Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY
Argus Val - speargv2. 02-JUN-2021 00:19:15. Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. -Argus Safety Japan.
SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Development Pipeline. An investigational long-acting granulocyte colony-stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia. The Biologics License Application (BLA) was filed in December, 2019, with a PDUFA date of October 24, 2020. On October 26, 2020, the company announced that the FDA informedthe company that
SPECTRUM PHARMACEUTICALS, INC. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has a late-stage pipeline that hasthe
INVESTOR RELATIONS
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncology and Hematology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, SPECTRUM PHARMACEUTICALS, INC. At Spectrum, we are committed to a corporate culture of compliance and integrity. Our Compliance and Ethics Program is a set of internal controls and standards that promote adherence to pharmaceutical industry statutes, regulations, and requirements of the federal health care programs with respect to the development, manufacturing, marketing and selling of products. SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGE Global Corporate Office Spectrum Pharmaceuticals. 11500 S. Eastern Avenue #240 Henderson, NV 89052 Phone: (702) 835-6300 Fax: (702)260-7405
SPECTRUM PHARMACEUTICALS, INC. Phase 2 trials; Ozarelix has the potential to be an important addition in treating hormone-dependent prostate cancer patients due to its ability to induce prolonged testosterone suppression without inducing an initial testosterone surge and associated risk of clinical flare and cancer progression observed in currently marketed LHRH agonists, as shown in healthy volunteers in early trials. SPECTRUM PHARMACEUTICALS, INC. Spectrum’s Medical Affairs department is the company’s primary customer-facing scientific exchange organization. The department includes functions dedicated to supporting the non-promotional scientific information needs of the healthcare community. These functions include Medical Information, Medical Communications, FieldMedical Affairs
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.ARGUS SAFETY 8.2.1
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. Development Pipeline. An investigational long-acting granulocyte colony-stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia. The Biologics License Application (BLA) was filed in December, 2019, with a PDUFA date of October 24, 2020. On October 26, 2020, the company announced that the FDA informedthe company that
SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ARGUS SAFETYARGUS SAFETY SUITEORACLE ARGUS SAFETY 8 1ORACLE ARGUS SAFETY DATABASEORACLE ARGUS SAFETY DATABASEORACLE ARGUS TRAINING Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY 8.2.1
09-NOV-2018 10:33:46 Oracle Health Sciences Safety Suite : Argus Safety - Argus Analytics - Empirica Topics - Argus Safety Japan - Argus Insight - Empirica Signal - Argus Affiliate - Argus Mart - Empirica Study - Argus Interchange - Argus Dossier - WebSDM - Argus Unblinding - Argus Reconciliation SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTISSPECTRUM ROLONTISSPECTRUMROLONTIS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. Development Pipeline. An investigational long-acting granulocyte colony-stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia. The Biologics License Application (BLA) was filed in December, 2019, with a PDUFA date of October 24, 2020. On October 26, 2020, the company announced that the FDA informedthe company that
SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ARGUS SAFETYARGUS SAFETY SUITEORACLE ARGUS SAFETY 8 1ORACLE ARGUS SAFETY DATABASEORACLE ARGUS SAFETY DATABASEORACLE ARGUS TRAINING Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY 8.2.1
09-NOV-2018 10:33:46 Oracle Health Sciences Safety Suite : Argus Safety - Argus Analytics - Empirica Topics - Argus Safety Japan - Argus Insight - Empirica Signal - Argus Affiliate - Argus Mart - Empirica Study - Argus Interchange - Argus Dossier - WebSDM - Argus Unblinding - Argus Reconciliation SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTISSPECTRUM ROLONTISSPECTRUMROLONTIS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGE Global Corporate Office Spectrum Pharmaceuticals. 11500 S. Eastern Avenue #240 Henderson, NV 89052 Phone: (702) 835-6300 Fax: (702)260-7405
SPECTRUM PHARMACEUTICALS, INC. Partnerships and Relationships. Our business model focuses on building a portfolio of novel and targeted drugs, primarily in the field of oncology, through acquisition and partnerships, rather than through in-house drug discovery. We then bring those drugs through the development process and make them available to patients. SPECTRUM PHARMACEUTICALS, INC. Spectrum conducts a range of clinical trials to bring new and novel products to the market. Please see the list below for a selected list of our trials of development drugs. Please note, by selecting these links, you will be going to an external site that is not controlled by or affiliated with Spectrum Pharmaceuticals SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC.STOCK INFORMATION
The Investor Relations website contains information about Spectrum Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. SPECTRUM PHARMACEUTICALS, INC. Ozarelix is a Luteinizing Hormone Releasing Hormone (LHRH) antagonist (a substance that blocks the effects of a natural hormone found in the body). Mechanistically, LHRH antagonists exert rapid inhibition of luteinizing hormone and follicle stimulating hormone with an accompanying rapid decrease in sex hormones and would therefore beexpected
SPECTRUM PHARMACEUTICALS TO PARTICIPATE IN TWO UPCOMING 16 hours ago · HENDERSON, Nev.--(BUSINESS WIRE)--May 27, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences: Jefferies Virtual SPECTRUM PHARMACEUTICALS TO PRESENT DATA FOR POZIOTINIB IN HENDERSON, Nev.--(BUSINESS WIRE)--May 28, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations. This poster presentation will be available at the 2021 ASCO Annual MeetingARGUS SAFETY
Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart. SPECTRUM PHARMACEUTICALS PRESENTS POZIOTINIB DATA IN Robert Uhl Managing Director, Westwicke ICR 858.356.5932 robert.uhl@westwicke.com Kurt Gustafson Chief Financial Officer 949.788.6700 InvestorRelations@sppirx.com SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ARGUS SAFETYARGUS SAFETY SUITEORACLE ARGUS SAFETY 8 1ORACLE ARGUS SAFETY DATABASEORACLE ARGUS SAFETY DATABASEORACLE ARGUS TRAINING Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY 8.2.1
09-NOV-2018 10:33:46 Oracle Health Sciences Safety Suite : Argus Safety - Argus Analytics - Empirica Topics - Argus Safety Japan - Argus Insight - Empirica Signal - Argus Affiliate - Argus Mart - Empirica Study - Argus Interchange - Argus Dossier - WebSDM - Argus Unblinding - Argus Reconciliation SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTISSPECTRUM ROLONTISSPECTRUMROLONTIS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS ANNOUNCES INITIATION OF THE This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has alate-stage pipeline
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Welcome to the Spectrum Pharmaceuticals, Inc. Career site! The Spectrum Pharmaceuticals, Inc. organization firmly believes that our employees drive the success of the company. With success in mind as the ultimate goal, we strive to create and provide an environment that offers challenging, stimulating and financially rewardingopportunities.
SPECTRUM PHARMACEUTICALS, INC. Poziotinib is designed to be small and flexible. Poziotinib is an investigational drug not approved by the FDA. In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ARGUS SAFETYARGUS SAFETY SUITEORACLE ARGUS SAFETY 8 1ORACLE ARGUS SAFETY DATABASEORACLE ARGUS SAFETY DATABASEORACLE ARGUS TRAINING Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart.ARGUS SAFETY 8.2.1
09-NOV-2018 10:33:46 Oracle Health Sciences Safety Suite : Argus Safety - Argus Analytics - Empirica Topics - Argus Safety Japan - Argus Insight - Empirica Signal - Argus Affiliate - Argus Mart - Empirica Study - Argus Interchange - Argus Dossier - WebSDM - Argus Unblinding - Argus Reconciliation SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTISSPECTRUM ROLONTISSPECTRUMROLONTIS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS ANNOUNCES INITIATION OF THE This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGE Global Corporate Office Spectrum Pharmaceuticals. 11500 S. Eastern Avenue #240 Henderson, NV 89052 Phone: (702) 835-6300 Fax: (702)260-7405
SPECTRUM PHARMACEUTICALS, INC. Partnerships and Relationships. Our business model focuses on building a portfolio of novel and targeted drugs, primarily in the field of oncology, through acquisition and partnerships, rather than through in-house drug discovery. We then bring those drugs through the development process and make them available to patients. SPECTRUM PHARMACEUTICALS, INC. Spectrum conducts a range of clinical trials to bring new and novel products to the market. Please see the list below for a selected list of our trials of development drugs. Please note, by selecting these links, you will be going to an external site that is not controlled by or affiliated with Spectrum Pharmaceuticals SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC. SPECTRUM PHARMACEUTICALS, INC. Phase 2 trials; Ozarelix has the potential to be an important addition in treating hormone-dependent prostate cancer patients due to its ability to induce prolonged testosterone suppression without inducing an initial testosterone surge and associated risk of clinical flare and cancer progression observed in currently marketed LHRH agonists, as shown in healthy volunteers in early trials.STOCK INFORMATION
The Investor Relations website contains information about Spectrum Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. SPECTRUM PHARMACEUTICALS TO PARTICIPATE IN TWO UPCOMING 10 hours ago · HENDERSON, Nev.--(BUSINESS WIRE)--May 27, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences: Jefferies Virtual SPECTRUM PHARMACEUTICALS TO PRESENT DATA FOR POZIOTINIB IN HENDERSON, Nev.--(BUSINESS WIRE)--May 28, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations. This poster presentation will be available at the 2021 ASCO Annual MeetingARGUS SAFETY
Oracle Health Sciences Safety Suite : - Argus Safety. - Argus Analytics. - Empirica Topics. - Argus Safety Japan. - Argus Insight. - Empirica Signal. - Argus Affiliate. - Argus Mart. SPECTRUM PHARMACEUTICALS PRESENTS POZIOTINIB DATA IN Robert Uhl Managing Director, Westwicke ICR 858.356.5932 robert.uhl@westwicke.com Kurt Gustafson Chief Financial Officer 949.788.6700 InvestorRelations@sppirx.com SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Focused on the Future. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology andoncology.
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Search Current Openings; Note to recruiters: Spectrum Pharmaceuticals Inc. only accepts applications or inquiries directly from candidates for posted or future positions. Spectrum has no obligation to provide any form of compensation in return for any unsolicited referrals, references or resumés received without a previously established recruiting contract. SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ARGUS SAFETYARGUS SAFETY SUITEORACLE ARGUS SAFETY 8 1ORACLE ARGUS SAFETY DATABASEORACLE ARGUS SAFETY DATABASEORACLE ARGUS TRAINING - Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
ARGUS SAFETY 8.2.1
09-NOV-2018 10:33:46 Oracle Health Sciences Safety Suite : Argus Safety - Argus Analytics - Empirica Topics - Argus Safety Japan - Argus Insight - Empirica Signal - Argus Affiliate - Argus Mart - Empirica Study - Argus Interchange - Argus Dossier - WebSDM - Argus Unblinding - Argus Reconciliation SPECTRUM PHARMACEUTICALS ANNOUNCES INITIATION OF THE This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTISSPECTRUM ROLONTISSPECTRUMROLONTIS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGEOUR COMPANYDEVELOPMENT PIPELINEINVESTOR RELATIONSMEDICAL PROFESSIONALSCAREERSCONTACT US Focused on the Future. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology andoncology.
SPECTRUM PHARMACEUTICALS, INC. ROLONTIS ® (eflapegrastim) data suggest that the human IgG4-derived Fc fragment of eflapegrastim interacts with a specific Fc receptor called FcRn, which is expressed in endothelial cells and in bone marrow, and is thought to prolong its retention in these tissues.. ROLONTIS ® (eflapegrastim) is an investigational drug not approved bythe FDA.
SPECTRUM PHARMACEUTICALS, INC. Search Current Openings; Note to recruiters: Spectrum Pharmaceuticals Inc. only accepts applications or inquiries directly from candidates for posted or future positions. Spectrum has no obligation to provide any form of compensation in return for any unsolicited referrals, references or resumés received without a previously established recruiting contract. SPECTRUM PHARMACEUTICALS, INC. This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SPECTRUM PHARMACEUTICALS, INC. Kurt Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industryorganizations.
ANNUAL REPORTS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ARGUS SAFETYARGUS SAFETY SUITEORACLE ARGUS SAFETY 8 1ORACLE ARGUS SAFETY DATABASEORACLE ARGUS SAFETY DATABASEORACLE ARGUS TRAINING - Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
ARGUS SAFETY 8.2.1
09-NOV-2018 10:33:46 Oracle Health Sciences Safety Suite : Argus Safety - Argus Analytics - Empirica Topics - Argus Safety Japan - Argus Insight - Empirica Signal - Argus Affiliate - Argus Mart - Empirica Study - Argus Interchange - Argus Dossier - WebSDM - Argus Unblinding - Argus Reconciliation SPECTRUM PHARMACEUTICALS ANNOUNCES INITIATION OF THE This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTISSPECTRUM ROLONTISSPECTRUMROLONTIS
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of SPECTRUM PHARMACEUTICALS, INC. A GLOBAL COMMERCIAL-STAGE Global Corporate Office Spectrum Pharmaceuticals. 11500 S. Eastern Avenue #240 Henderson, NV 89052 Phone: (702) 835-6300 Fax: (702)260-7405
SPECTRUM PHARMACEUTICALS, INC. We establish strategic alliances with leading biotechnology and pharmaceutical companies, represented by the list below, to leverage their strengths, mitigate risk inherent in the drug development process, accelerate drug development timelines, and generate cash through milestones, royalties and SPECTRUM PHARMACEUTICALS, INC. Eflapegrastim clinical trials*. SPI-GCF-104: Same Day Dosing. Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After the Same-Day, Varying Dosing Time Schedules of Eflapegrastim Administration in Patients with Breast-Cancer Receiving Docetaxel andCyclophosphamide
SPECTRUM PHARMACEUTICALS, INC. Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC. SPECTRUM PHARMACEUTICALS, INC. Phase 2 trials; Ozarelix has the potential to be an important addition in treating hormone-dependent prostate cancer patients due to its ability to induce prolonged testosterone suppression without inducing an initial testosterone surge and associated risk of clinical flare and cancer progression observed in currently marketed LHRH agonists, as shown in healthy volunteers in early trials.STOCK INFORMATION
The Investor Relations website contains information about Spectrum Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. SPECTRUM PHARMACEUTICALS TO PARTICIPATE IN TWO UPCOMING 8 hours ago · HENDERSON, Nev.--(BUSINESS WIRE)--May 27, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences: Jefferies Virtual SPECTRUM PHARMACEUTICALS TO PRESENT DATA FOR POZIOTINIB IN HENDERSON, Nev.--(BUSINESS WIRE)--May 28, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations. This poster presentation will be available at the 2021 ASCO Annual MeetingARGUS SAFETY
- Argus Safety - Argus Analytics - Empirica Topics - Argus SafetyJapan
SPECTRUM PHARMACEUTICALS PRESENTS POZIOTINIB DATA IN Robert Uhl Managing Director, Westwicke ICR 858.356.5932 robert.uhl@westwicke.com Kurt Gustafson Chief Financial Officer 949.788.6700 InvestorRelations@sppirx.com* __ __
* Our Company
* Our Company
* Company Philosophy * Corporate Compliance* Management
* Board of Directors * Development Pipeline* Pipeline
* ROLONTIS®
* Poziotinib
* Clinical Trials
* Glossary
* Investor Relations * Investor Relations* Press Releases
* Events and Presentations * Corporate Governance * Corporate Governance* Management
* Board of Directors * Committee Composition * Insider Transactions * Annual Report and Proxy Information * Financial Information * Financial Information* SEC Filings
* 10K Annual Reports* Quarterly Results
* Financial Statements* Stock Information
* Stock Information
* Historic Stock Lookup * Investment Calculator * Stock-Split History* Analyst Coverage
* Ownership Profile
* Investor FAQs
* Medical Affairs
* Medical Affairs
* Medical Information* Grants
* Expanded Access Program* Careers
* Contact Us
* Funding & Support
*
POZIOTINIB IN EXON 20 INSERTION MUTATION IN NSCLC Poziotinib is a novel, oral quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the HER family of tyrosine-kinase receptors, as well as HER receptor mutations. This in turn can lead to inhibition of the proliferation of tumor cells that overexpress these receptors. This drug has not yet been approved by the FDA. Click here for Poziotinib data from WCLC presentation*
OFFERING HOPE
Learn more about Spectrum's Late-Stage Products*
SMALL COMPANY SPIRIT, BIG COMPANY PERFORMANCE Our people are our best asset. Learn more.*
MAKING A DIFFERENCE
IN THE LIVES OF PATIENTS EVERY DAY*
FOCUSED ON VALUE
Spectrum has a proven record of success. Learn more. OUR COMMITMENT TO PATIENTS At Spectrum Pharmaceuticals, Inc., we bring the expertise and passion for excellence of our team to acquire, develop and commercialize novel and targeted pharmaceuticals for unmet medical needs while building value for our shareholders.__ More
FOCUSED ON THE FUTURE Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has a late-stage pipeline that has the potential to transform the company. SPECTRUM HAS TWO DRUGS IN ADVANCED DEVELOPMENT: __ROLONTIS® (EFLAPEGRASTIM) ROLONTIS® (eflapegrastim), being developed for chemotherapy-induced neutropenia in patients with breast cancer. Learn more »__POZIOTINIB
Poziotinib for a mutation in Non Small Cell Lung Cancer (NSCLC), and for patients with breast cancer. Learn more » EXPANDING PATIENT OPTIONS Our passion to deliver additional options for patients suffering from cancer is behind every action we take. We will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes. Learn more about the Spectrumphilosophy.
The Spectrum PhilosophyCOMPANY HIGHLIGHTS
View All Press Releases__June 4, 2021
SPECTRUM PHARMACEUTICALS PRESENTS POZIOTINIB DATA IN PATIENTS WITH BRAIN METASTASES FROM THE ZENITH20 CLINICAL TRIAL AT 2021 ASCO ANNUALMEETING
Read More __
__June 1, 2021
SPECTRUM PHARMACEUTICALS ANNOUNCES THAT THE ROLONTIS® (EFLAPEGRASTIM) PRE-APPROVAL INSPECTION HAS BEEN INITIATEDRead More __
__May 28, 2021
SPECTRUM PHARMACEUTICALS TO PRESENT DATA FOR POZIOTINIB IN PATIENTS WITH BRAIN METASTASES AT THE UPCOMING 2021 ASCO ANNUAL MEETINGRead More __
OUR COMPANY
* Company Philosophy * Corporate Compliance* Management
* Board of Directors DEVELOPMENT PIPELINE* Pipeline
* ROLONTIS®
* Poziotinib
* Clinical Trials
* Glossary
INVESTOR RELATIONS
* Press Releases
* Events and Presentations * Corporate Governance * Annual Report and Proxy Information * Financial Information* Stock Information
* Investor FAQs
MEDICAL AFFAIRS
* Medical Information* Grants
* Expanded Access ProgramCAREERS
CONTACT US
* Funding & Support
------------------------- This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law. All contents copyright Spectrum Pharmaceuticals, Inc. © 2021. All Rights Reserved. PP-ALL-00-0048* Site Map
* Privacy Policy
* Terms of Use
* Linking Policy
* Contact Us
* Remote Support
* Webmail
____
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0